{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:40:05Z","timestamp":1777480805022,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s10549-022-06731-z","type":"journal-article","created":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T09:02:43Z","timestamp":1662800563000},"page":"255-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer"],"prefix":"10.1007","volume":"196","author":[{"given":"Hideki","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0068-4487","authenticated-orcid":false,"given":"Hiroshi","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Hirotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Amemiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,10]]},"reference":[{"key":"6731_CR1","unstructured":"Available at https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html Accessed on 30, April, 2022."},{"key":"6731_CR2","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1128\/mcb.9.3.1165","volume":"9","author":"RM Hudziak","year":"1989","unstructured":"Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165\u20131172. https:\/\/doi.org\/10.1128\/mcb.9.3.1165","journal-title":"Mol Cell Biol"},{"key":"6731_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/BF00918679","volume":"11","author":"HM Shepard","year":"1991","unstructured":"Shepard HM, Lewis GD, Sarup JC et al (1991) Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11:117\u2013127. https:\/\/doi.org\/10.1007\/BF00918679","journal-title":"J Clin Immunol"},{"key":"6731_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792. https:\/\/doi.org\/10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"key":"6731_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","volume":"28","author":"S Dawood","year":"2010","unstructured":"Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92\u201398. https:\/\/doi.org\/10.1200\/JCO.2008.19.9844","journal-title":"J Clin Oncol"},{"key":"6731_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684. https:\/\/doi.org\/10.1056\/NEJMoa052122","journal-title":"N Engl J Med"},{"key":"6731_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377\u2013384. https:\/\/doi.org\/10.1016\/S0140-6736(09)61964-4","journal-title":"Lancet"},{"key":"6731_CR8","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","volume":"28","author":"M Untch","year":"2010","unstructured":"Untch M, Rezai M, Loibl S et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28:2024\u20132031. https:\/\/doi.org\/10.1200\/JCO.2009.23.8451","journal-title":"J Clin Oncol"},{"key":"6731_CR9","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","volume":"23","author":"AU Buzdar","year":"2005","unstructured":"Buzdar AU, Ibrahim NK, Francis D et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676\u20133685. https:\/\/doi.org\/10.1200\/JCO.2005.07.032","journal-title":"J Clin Oncol"},{"key":"6731_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"key":"6731_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature11017","volume":"486","author":"PJ Stephens","year":"2012","unstructured":"Stephens PJ, Tarpey PS, Davies H et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400\u2013404. https:\/\/doi.org\/10.1038\/nature11017","journal-title":"Nature"},{"key":"6731_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bcp.2018.11.004","volume":"162","author":"FM Vallette","year":"2019","unstructured":"Vallette FM, Olivier C, Lezot F et al (2019) Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer. Biochem Pharmacol 162:169\u2013176. https:\/\/doi.org\/10.1016\/j.bcp.2018.11.004","journal-title":"Biochem Pharmacol"},{"key":"6731_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112666","author":"HF Cabanos","year":"2021","unstructured":"Cabanos HF, Hata AN (2021) Emerging insights into targeted therapy-tolerant persister cells in cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13112666","journal-title":"Cancers (Basel)"},{"key":"6731_CR14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ejca.2014.01.003","volume":"50","author":"JC Thery","year":"2014","unstructured":"Thery JC, Spano JP, Azria D, Raymond E, Penault Llorca F (2014) Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur J Cancer 50:892\u2013901. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.003","journal-title":"Eur J Cancer"},{"key":"6731_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12032-016-0857-2","volume":"34","author":"Y Hirotsu","year":"2017","unstructured":"Hirotsu Y, Nakagomi H, Amemiya K et al (2017) Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. Med Oncol 34:3. https:\/\/doi.org\/10.1007\/s12032-016-0857-2","journal-title":"Med Oncol"},{"key":"6731_CR16","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1002\/cam4.950","volume":"5","author":"K Amemiya","year":"2016","unstructured":"Amemiya K, Hirotsu Y, Goto T et al (2016) Touch imprint cytology with massively parallel sequencing (TIC-seq): a simple and rapid method to snapshot genetic alterations in tumors. Cancer Med 5:3426\u20133436. https:\/\/doi.org\/10.1002\/cam4.950","journal-title":"Cancer Med"},{"key":"6731_CR17","doi-asserted-by":"publisher","first-page":"D805","DOI":"10.1093\/nar\/gku1075","volume":"43","author":"SA Forbes","year":"2015","unstructured":"Forbes SA, Beare D, Gunasekaran P et al (2015) COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43:D805-811. https:\/\/doi.org\/10.1093\/nar\/gku1075","journal-title":"Nucleic Acids Res"},{"key":"6731_CR18","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H et al (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45:1439\u20131445. https:\/\/doi.org\/10.1038\/ng.2822","journal-title":"Nat Genet"},{"key":"6731_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mgg3.120","volume":"3","author":"Y Hirotsu","year":"2015","unstructured":"Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M (2015) Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med 3:121\u2013129","journal-title":"Mol Genet Genomic Med"},{"key":"6731_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/mgg3.157","volume":"3","author":"Y Hirotsu","year":"2015","unstructured":"Hirotsu Y, Nakagomi H, Sakamoto I et al (2015) Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. Mol Genet Genomic Med 3:459\u2013466","journal-title":"Mol Genet Genomic Med"},{"key":"6731_CR21","first-page":"12663","volume":"5","author":"Y Hirotsu","year":"2016","unstructured":"Hirotsu Y, Zheng TH, Amemiya K, Mochizuki H, Guleng B, Omata M (2016) Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma. Hepatol Res 5:12663","journal-title":"Hepatol Res"},{"key":"6731_CR22","unstructured":"Available at https:\/\/www.oncokb.org\/ Accessed 17 Jan 2021"},{"key":"6731_CR23","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nmeth.2883","volume":"11","author":"A Roth","year":"2014","unstructured":"Roth A, Khattra J, Yap D et al (2014) PyClone: statistical inference of clonal population structure in cancer. Nat Methods 11:396\u2013398. https:\/\/doi.org\/10.1038\/nmeth.2883","journal-title":"Nat Methods"},{"key":"6731_CR24","doi-asserted-by":"publisher","first-page":"31133","DOI":"10.18632\/oncotarget.16096","volume":"8","author":"T Goto","year":"2017","unstructured":"Goto T, Hirotsu Y, Mochizuki H et al (2017) Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile. Oncotarget 8:31133\u201331143. https:\/\/doi.org\/10.18632\/oncotarget.16096","journal-title":"Oncotarget"},{"key":"6731_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","volume":"28","author":"J Baselga","year":"2010","unstructured":"Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138\u20131144. https:\/\/doi.org\/10.1200\/JCO.2009.24.2024","journal-title":"J Clin Oncol"},{"key":"6731_CR26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724\u2013734. https:\/\/doi.org\/10.1056\/NEJMoa1413513","journal-title":"N Engl J Med"},{"key":"6731_CR27","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783\u20131791. https:\/\/doi.org\/10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"6731_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382:610\u2013621. https:\/\/doi.org\/10.1056\/NEJMoa1914510","journal-title":"N Engl J Med"},{"key":"6731_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.critrevonc.2019.05.001","volume":"139","author":"C Vernieri","year":"2019","unstructured":"Vernieri C, Milano M, Brambilla M et al (2019) Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol 139:53\u201366. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.05.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"6731_CR30","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1158\/1078-0432.CCR-10-0410","volume":"16","author":"J Sperinde","year":"2010","unstructured":"Sperinde J, Jin X, Banerjee J et al (2010) Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 16:4226\u20134235. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0410","journal-title":"Clin Cancer Res"},{"key":"6731_CR31","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-09-0295","volume":"8","author":"D Mitra","year":"2009","unstructured":"Mitra D, Brumlik MJ, Okamgba SU et al (2009) An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 8:2152\u20132162. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0295","journal-title":"Mol Cancer Ther"},{"key":"6731_CR32","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2353\/ajpath.2010.090885","volume":"177","author":"FJ Esteva","year":"2010","unstructured":"Esteva FJ, Guo H, Zhang S et al (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:1647\u20131656. https:\/\/doi.org\/10.2353\/ajpath.2010.090885","journal-title":"Am J Pathol"},{"key":"6731_CR33","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","volume":"93","author":"Y Lu","year":"2001","unstructured":"Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852\u20131857. https:\/\/doi.org\/10.1093\/jnci\/93.24.1852","journal-title":"J Natl Cancer Inst"},{"key":"6731_CR34","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1158\/1078-0432.CCR-07-0701","volume":"13","author":"CA Ritter","year":"2007","unstructured":"Ritter CA, Perez-Torres M, Rinehart C et al (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909\u20134919. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0701","journal-title":"Clin Cancer Res"},{"key":"6731_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.critrevonc.2017.02.022","volume":"112","author":"SP Corona","year":"2017","unstructured":"Corona SP, Ravelli A, Cretella D et al (2017) CDK4\/6 inhibitors in HER2-positive breast cancer. Crit Rev Oncol Hematol 112:208\u2013214. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.022","journal-title":"Crit Rev Oncol Hematol"},{"key":"6731_CR36","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","volume":"16","author":"M Mikubo","year":"2021","unstructured":"Mikubo M, Inoue Y, Liu G, Tsao MS (2021) Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J Thorac Oncol 16:1798\u20131809. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.017","journal-title":"J Thorac Oncol"},{"key":"6731_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143517","author":"H Li","year":"2021","unstructured":"Li H, Prever L, Hirsch E, Gulluni F (2021) Targeting PI3K\/AKT\/mTOR signaling pathway in breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13143517","journal-title":"Cancers (Basel)"},{"key":"6731_CR38","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Stefanovska B, Lusque A et al (2020) Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol 31:377\u2013386. https:\/\/doi.org\/10.1016\/j.annonc.2019.11.006","journal-title":"Ann Oncol"},{"key":"6731_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature14669","volume":"525","author":"S Koren","year":"2015","unstructured":"Koren S, Reavie L, Couto JP et al (2015) PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature 525:114\u2013118. https:\/\/doi.org\/10.1038\/nature14669","journal-title":"Nature"},{"key":"6731_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature14665","volume":"525","author":"A Van Keymeulen","year":"2015","unstructured":"Van Keymeulen A, Lee MY, Ousset M et al (2015) Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 525:119\u2013123. https:\/\/doi.org\/10.1038\/nature14665","journal-title":"Nature"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06731-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06731-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06731-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T21:06:06Z","timestamp":1666213566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06731-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,10]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6731"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06731-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,10]]},"assertion":[{"value":"18 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients provided written informed consent for the genomic research study, which was performed in accordance with the protocols approved by the Institutional Review Board at our hospital (No.2018-6).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent for the genomic research study, which was performed in accordance with the protocols approved by the Institutional Review Board at our hospital (No.2018-6).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participants"}},{"value":"Consent for publication was included in the written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}